Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash & Equivalents (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Cash & Equivalents for 2 consecutive years, with $183.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Cash & Equivalents rose 224.5% to $183.0 million in Q3 2023 year-over-year; TTM through Sep 2023 was $183.0 million, a 224.5% increase, with the full-year FY2022 number at $47.7 million, changed N/A from a year prior.
  • Cash & Equivalents was $183.0 million for Q3 2023 at LENZ Therapeutics, up from $128.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $185.1 million in Q1 2022 to a low of $8.0 million in Q1 2023.